Moxifloxacin

Active ingredient: Moxifloxacin Hydrochloride

In short: Moxifloxacin tablets are indicated in adult patients for the treatment of Community Acquired Pneumonia caused by susceptible isolates of Streptococcus pneumoniae (including multi-drug resistant Streptococcus pneumoniae [MDRSP]), Haemophilus influenzae, Moraxella catarrhalis, methicillin-susceptible

Forms & strengthsMoxifloxacin Tablets USP, 400 mg are available as Beige colored, capsule shaped, biconvex tablets debossed ‘112’ on one side and plain on other side.
LabelPD-Rx Pharmaceuticals, Inc.
Label updatedOct 29, 2026

What is Moxifloxacin used for?

Moxifloxacin tablets are indicated in adult patients for the treatment of Community Acquired Pneumonia caused by susceptible isolates of

Streptococcus pneumoniae (including multi-drug resistant

Streptococcus pneumoniae [MDRSP]),

Haemophilus influenzae, Moraxella catarrhalis, methicillin-susceptible Staphylococcus aureus, Klebsiella pneumoniae, Mycoplasma pneumoniae, or Chlamydophila pneumoniae .

MDRSP isolates are isolates resistant to two or more of the following antibacterial drugs: penicillin (minimum inhibitory concentrations [MIC] ≥ 2 mcg/mL), 2nd generation cephalosporins (for example, cefuroxime), macrolides, tetracyclines, and trimethoprim/sulfamethoxazole.

Moxifloxacin tablets are indicated in adult patients for the treatment of Uncomplicated Skin and Skin Structure Infections caused by susceptible isolates of methicillin-susceptible

Staphylococcus aureus or Streptococcus pyogenes .

Moxifloxacin tablets are indicated in adult patients for the treatment of Complicated Skin and Skin Structure Infections caused by susceptible isolates of methicillin-susceptible

Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, or Enterobacter cloacae . …

âš  Boxed warning (FDA's strongest warning)

•

Fluoroquinolones, including moxifloxacin, have been associated with disabling and potentially irreversible serious adverse reactions that have occurred together

, including:

•

Tendinitis and tendon rupture

•

Peripheral neuropathy

•

Central nervous system effects

Discontinue moxifloxacin, immediately and avoid the use of fluoroquinolones, including moxifloxacin, in patients who experience any of these serious adverse reactions

.

•

Fluoroquinolones, including moxifloxacin, may exacerbate muscle weakness in patients with myasthenia gravis. Avoid moxifloxacin, in patients with known history of myasthenia gravis

.

•

Because fluoroquinolones, including moxifloxacin, have been associated with serious adverse reactions

, reserve moxifloxacin, for use in patients who have no alternative treatment options for the following indications:

•

Acute bacterial sinusitis

• Acute bacterial exacerbation of chronic bronchitis

Moxifloxacin dosage

The dose of moxifloxacin tablet is 400 mg (orally) once every 24 hours. The duration of therapy depends on the type of infection as described in

Table 1.

Table 1: Dosage and Duration of Therapy in Adult Patients

Type of Infection

a | Dose Every 24 hours | Duration

b (days)

Community Acquired Pneumonia (

1.1) | 400 mg | 7 to 14

Uncomplicated Skin and Skin Structure Infections (SSSI ) (

1.2) | 400 mg | 7

Complicated SSSI (

1.3) | 400 mg | 7 to 21

Complicated Intra-Abdominal Infections (

1.4) | 400 mg | 5 to 14

Plague (

1.5)

c | 400 mg | 10 to 14

Acute Bacterial Sinusitis (ABS) (

1.6) | 400 mg | 10

Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB) (

1.7) | 400 mg | 5

a Due to the designated pathogens

b Sequential therapy (intravenous to oral) may be instituted at the discretion of the physician

c Drug administration should begin as soon as possible after suspected or confirmed exposure to

Yersinia pestis.

Conversion of Intravenous to Oral Dosing in Adults

Intravenous formulation is indicated when it offers a route of administration advantageous to the patient (for example, patient cannot tolerate an oral dosage form). When switching from intravenous to oral formulation, no dosage adjustment is necessary. Patients whose therapy is started with moxifloxacin hydrochloride injection may be switched to moxifloxacin tablets when clinically indicated at the discretion of the physician.

Moxifloxacin Tablets

With Multivalent Cations

Administer moxifloxacin tablets at least 4 hours before or 8 hours after products containing magnesium, aluminum, iron or zinc, including antacids, sucralfate, multivitamins and didanosine buffered tablets for oral suspension or the pediatric powder for oral solution .

With Food

Moxifloxacin tablets can be taken with or without food, drink fluids liberally.

Missed Doses

If a dose is missed, it should be taken anytime but not later than 8 hours prior to the next scheduled dose. If less than 8 hours remain before the next dose, the missed dose should not be taken and treatment should be continued as prescribed with the next scheduled dose. Double doses should not be taken to compensate for a missed dose.

How to take Moxifloxacin — instructions & advice from the label

Advise the patient to read the FDA-approved patient labeling (Medication Guide)

Serious Adverse Reactions Advise patients to stop taking moxifloxacin if they experience an adverse reaction and to call their healthcare provider for advice on completing the full course of treatment with another antibacterial drug.

Inform patients of the following serious adverse reactions that have been associated with moxifloxacin or other fluoroquinolone use:

•

Disabling and potentially irreversible serious adverse reactions that may occur together: Inform patients that disabling and potentially irreversible serious adverse reactions, including tendinitis and tendon rupture, peripheral neuropathies, and central nervous system effects, have been associated with use of moxifloxacin and may occur together in the same patient. Inform patients to stop taking moxifloxacin immediately if they experience an adverse reaction and to call their healthcare provider. …

Warnings & precautions

Do not take this medicine if: Moxifloxacin tablets are contraindicated in persons with a history of hypersensitivity to moxifloxacin or any member of the quinolone class of antibacterials .

Fluoroquinolones, including moxifloxacin, have been associated with disabling and potentially irreversible serious adverse reactions from different body systems that can occur together in the same patient. Commonly seen adverse reactions include tendinitis, tendon rupture, arthralgia, myalgia, peripheral neuropathy, and central nervous system effects (hallucinations, anxiety, depression, insomnia, severe headaches, and confusion). These reactions can occur within hours to weeks after starting moxifloxacin. Patients of any age or without pre-existing risk factors have experienced these adverse reactions .

Discontinue moxifloxacin immediately at the first signs or symptoms of any serious adverse reaction. In addition, avoid the use of fluoroquinolones, including moxifloxacin, in patients who have experienced any of these serious adverse reactions associated with fluoroquinolones.

Fluoroquinolones, including moxifloxacin, have been associated with an increased risk of tendinitis and tendon rupture in all ages . This adverse reaction most frequently involves the Achilles tendon, and has also been reported with the rotator cuff (the shoulder), the hand, the biceps, the thumb, and other tendons. Tendinitis or tendon rupture can occur within hours or days of starting moxifloxacin or as long as several months after completion of therapy. Tendinitis and tendon rupture can occur bilaterally.

The risk of developing fluoroquinolone-associated tendinitis and tendon rupture is increased in patients over 60 years of age, in patients taking corticosteroid drugs, and in patients with kidney, heart or lung transplants. …

Moxifloxacin side effects

The following serious and otherwise important adverse reactions are discussed in greater detail in the warnings and precautions section of the label:

• Disabling and Potentially Irreversible Serious Adverse Reactions Including Tendinitis and Tendon Rupture, Peripheral Neuropathy, and Central Nervous System Effects

• Tendinitis and Tendon Rupture

• Peripheral Neuropathy

• Central Nervous System Effects

• Exacerbation of Myasthenia Gravis

• QT Prolongation

• Other Serious and Sometimes Fatal Adverse Reactions

• Hypersensitivity Reactions

• Risk of Aortic Aneurysm and Dissection

•

Clostridioides difficile-Associated Diarrhea

• Blood Glucose Disturbances

• Photosensitivity/Phototoxicity

• Development of Drug Resistant Bacteria

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The data described below reflect exposure to moxifloxacin in 14981 patients in 71 active controlled Phase II to IV clinical trials in different indications . The population studied had a mean age of 50 years (approximately 73% of the population was less than 65 years of age), 50% were male, 63% were Caucasian, 12% were Asian and 9% were Black. Patients received moxifloxacin 400 mg once daily oral, intravenous, or sequentially (intravenous followed by oral). …

Drug interactions

Fluoroquinolones, including moxifloxacin, form chelates with alkaline earth and transition metal cations. Oral administration of moxifloxacin with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the pediatric powder for oral solution, may substantially interfere with the absorption of moxifloxacin, resulting in systemic concentrations considerably lower than desired. Therefore, moxifloxacin should be taken at least 4 hours before or 8 hours after these agents

Fluoroquinolones, including moxifloxacin, have been reported to enhance the anticoagulant effects of warfarin or its derivatives in the patient population. In addition, infectious disease and its accompanying inflammatory process, age, and general status of the patient are risk factors for increased anticoagulant activity. Therefore the prothrombin time, International Normalized Ratio (INR), or other suitable anticoagulation tests should be closely monitored if moxifloxacin is administered concomitantly with warfarin or its derivatives . …

About this medicine

Moxifloxacin hydrochloride USP is a synthetic antibacterial agent for oral administration. Moxifloxacin, a fluoroquinolone, is available as the monohydrochloride salt of 1-cyclopropyl-7-[(S,S)-2,8-diazabicyclo[4.3.0]non-8-yl]-6-fluoro-8-methoxy-1,4-dihydro-4-oxo-3 quinoline carboxylic acid. It is a slightly yellow to yellow powder or crystals with a molecular weight of 437.9. Its molecular formula is C

21H

24FN

3O

4*HCl and its chemical structure is as follows

Moxifloxacin Tablets, USP are available as film-coated tablets containing 400 mg moxifloxacin (equivalent to 436.30 mg moxifloxacin hydrochloride, USP).

Inactive ingredients: colloidal silicon dioxide, croscarmellose sodium, hypromellose, iron oxide red, iron oxide yellow, magnesium stearate, microcrystalline cellulose, polyethylene glycol 400, polysorbate 80, sodium stearyl fumarate, talc and titanium dioxide.

How it works: Moxifloxacin is a member of the flouroquinolone class of antibacterial agents . …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 1c6f7150-a8f4-408f-956f-c26d37030cf4. Read the full official label on DailyMed.

Related medicines

Amoxicillin Azithromycin Doxycycline Amoxicillin and Clavulanate Cephalexin Valacyclovir Sulfamethoxazole and Trimethoprim Nitrofurantoin